BTIG Research Upgrades Endologix To Buy, Shares Gain

Analysts at BTIG Research upgraded Endologix ELGX from Neutral to Buy. The target price for Endologix is set to $17. Endologix shares have dropped 17.30% over the past 52 weeks, while the S&P 500 index has surged 20.02% in the same period. Endologix's shares surged 2.93% to $13.68 in pre-market trading.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: UpgradesAnalyst RatingsBTIG Research
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!